CD56阳性对急性早幼粒细胞白血病患者预后的影响

doi:10.3969/j.issn.2095-9400.2019.02.004

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1256 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the expression of CD56 antigen in de-novo acute promyelocytic leukemia (APL) and to analyze the immuno-features and surviva1 of patients with positive CD56 expression.Methods: The expression of CD56 in bone marrow was detected by flow cytometry. Patients of de-novo acute promyelocytic leukemia who visited Wenzhou Central Hospital from May 2007 to October 2012 were followed up and their clinical data were analyzed. Immuno-features and prognosis were compared between patients expressing and nonexpressing CD56. Results: Of 64 patients, 12 (18.75%) were positive for CD56. There were no statistical differences in terms of CD9, CD11b, CD15, CD19, CD117, HLA-DR surface antigen markers between CD56+ and CD56- groups (P>0.05). Expressions of CD56 were significantly associated with coexpression of CD2 and CD34 (25.00% vs. 3.85%, P=0.042; 41.67% vs. 3.85%, P=0.001). The complete remission, relapse rate, 3-year median overall survival (OS) period and 3-year overall survival rate showed no significant differences between CD56+ and CD56- groups (P>0.05), while extramedullary relapse rate (27.27% vs. 4.55%, P<0.05), 3-year disease free-survival (DFS) rate (54.55% vs. 86.36%, P<0.05) indicated significant differences. Conclusion: The expression of CD56 appeared to be one of adverse prognostic factors in de-novo APL.

Key words： antigens, CD56 leukemia, promyelocytic, acute prognosis

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Yuemiao
	YU Kang
	ZHENG Cuiping
	ZHOU Wenjin
	LIU Zhen

URL:

https://xb.wmu.edu.cn/EN/10.3969/j.issn.2095-9400.2019.02.004 OR https://xb.wmu.edu.cn/EN/Y2019/V49/I2/96

[1] SUZUKI R, OHTAKE S, TAKEUCHI J, et a1. The clinical characteristics of CD7+ CD56+ acute myeloid leukemias other than M0[J]. Int J Hematol, 2010, 91(2): 303-309.
[2] 马荣军, 朱尊民, 袁晓莉, 等. 成人急性早幼粒细胞白血病预后相关因素分析[J]. 中华血液学杂志, 2017, 38(7): 592-596.
[3] 宋斌, 陈雁, 吴修伟, 等. 176例成人急性髓细胞白血病免疫表型分析及其与疗效、复发关系的研究[J]. 标记免疫分析与临床, 2016, 23(11): 1337-1340.
[4] 张之南, 沈悌. 血液病诊断及疗效标准[M]. 北京: 科学出版社, 2007.
[5] 陈芳, 胡延平, 王孝会, 等. 急性早幼粒细胞白血病免疫表型特点[J]. 中国实验血液学杂志, 2016, 24(2): 321-325.
[6] 宫丹, 李薇, 胡亮钉, 等. 中国t(8;21)AML患者临床特征及预后分析: 一项多中心回顾性研究[J]. 中国实验血液学杂志, 2017, 25(4): 980-986.
[7] 赵慧慧, 黄佳瑜, 朱雨, 等. CD56阳性老年急性髓系白血病患者的临床特征及预后分析[J]. 老年医学与保健, 2017, 16(21): 2125-2128.
[8] ITO S, ISHIDA Y, OYAKE T, et al. Clinical and biological significance of CD56 antigen expression in acute promyelocytic leukemia[J]. Leuk Lymphoma, 2004, 45(9): 1783-1789.
[9] MONTESINOS P, RAYON C, VELLENGA E, et al. Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-transretinoic acid and anthracycline-based regimens[J]. Blood, 2011, 117(6): 1799-1805.
[10] ONO T, TAKESHITA A, Kishimoto Y, et al. Expression of CD56 is an unfavorable prognosticfactor for acute promyelocytic leukemia with higherinitial white blood cell counts [J]. Cancer Sci, 2014, 105(1): 97-104.
[11] LAUNDER T M, BRAY R A, STEMPORA L, et al. Lymphoid-associated antigen expression by acute myeloid leuke-mia[J]. Am J Clin Pathol, 1996, 106(2): 185-191.
[12] CHAPIRO E, DELABESSE E, ASNAFI V, et al. Expression of T-lineage-affiliated transcripts and TCR rearrangements in acute promyelocytic leukemia: implications for the cellular target of t (15;17)[J]. Blood, 2006, 108(10): 3484-3493.
[13] XU F, YIN C X, WANG C L, et al. Immunophenotypes and immune markers associated with acute promyelocytic leukemia prognosis[J]. Dis Markers, 2014, 2014: 421906.
[14] KAITO K, KATAYAMA T, MASUOKA H, et al. CD2+ acute promyelocytic leukemia is associated with leukocytosis, variant morphology and poorer prognosis[J]. Clin Lab Haematol, 2005, 27(5): 307-311.
[15] 董婷, 蒋雅先, 李正发, 等. 急性早幼粒细胞白血病的细胞表面免疫分子的检测和分析[J]. 细胞与分子免疫学杂志, 2017, 33(5): 664-667, 676.
[16] 刘玉玉, 焦玉燕, 李斑斑, 等. 急性早幼粒细胞白血病早期死亡危险因素分析[J]. 中国现代医生, 2015, 53(16): 15-17.
[17] FERRARA F, MORABITO F, MARTINO B, et al. CD56 expression is an indicator ofpoor clinical outcome in patients with acute promyelocytic leukemia treatedwith simultaneous all-trans-retinoic acid and chemotherapy[J]. J Clin Oncol, 2000, 18(6): 1295-1300.
[18] DE LA SERNA J, MONTESINOS P, VELLENGA E, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin[J]. Blood, 2008, 111(7): 3395-3402.
[19] ILAND H J, BRADSTOCK K, SUPPLE S G, et al. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)[J]. Blood, 2012, 120: 1570-1580.
[20] TIWARI D, BOSE P D, SULTANA R, et al. Preterm delivery and associated negative pregnancy outcome-A tale of faulty progesterone receptor signalling pathway and linked derailed immunomodulation: A study from Northeast India [J]. J Reprod Immunol, 2016, 118: 76-84.